<! DOCTYPE = html>
<html>
<title>CS657 - Prescription</title>
<style>
div.container {
		width: 100%;
		border: 1px solid gray;
}

header{
		padding: 0.5em;
		#color: black;
		background-color: orange;
		clear: left;
		text-align: center;
}
.footer{
		padding : 1em;
		background-color: orange;
		text-align: center;
		<!--- position: fixed;>
		bottom : 0;
		width : 100%;
}

nav {
		float: left;
		max-width: 160px;
		margin: 0;
		padding: 1em;
}

nav ul {
		list-style-type: none;
		padding: 0;
}
	 
nav ul a {
		text-decoration: none;
}

article {
		margin-left: 170px;
		border-left: 1px solid gray;
		padding: 1em;
		overflow: hidden;
}
table {
		font-family: arial, sans-serif;
		border-collapse: collapse;
		width: 80%;
}

td, th {
		border: 4px solid #000000;
		text-align: middle;
		padding: 8px;
}

tr:nth-child(even) {
		background-color: #eeeeee;
}	

div.box {
		background-color: white;
		width: 300px;
		border: 2px solid green;
		padding: 10px;
		margin: 25px;
}
</style>
<body>
<div class="container">
	<header><h1>
		IIT Kanpur Medical Labs</h1>
	</header>
	<hr>	<h2> Precription for the query: </h2>
	<div class="box">
	back pain, fever, nausea, urinary incontinence, stress, urge
	</div>
	<hr>	<h2>
		Identified Disease: </h2>
	<div class="box">
	Urination Disorders
	</div>
	<hr>	<h2>More Symptoms: </h2>
	<div class="box">
	Ataxia, Spasm, Headache, Quadriplegia, Flank Pain
	</div>
		<hr><h2>
Medication:</h2>
<table>
	<tr>
		<th>Serial No</th>
		<th>Drug Name</th>
		<th>Group</th>
		<th>Indication</th>
	</tr>	<tr>
		<td>1.</td>
		<td>Polythiazide</td>
		<td>Approved</td>
		<td>Polythiazide is a thiazide diuretic used to decrease edema and decrease blood pressure.</td>
	</tr>	<tr>
		<td>2.</td>
		<td>Olive oil</td>
		<td>Approved</td>
		<td>For use in adults as a source of calories and fatty acids in total parenteral nutrition [FDA Label]. Sometimes used as an additive in cosmetic products.</td>
	</tr>	<tr>
		<td>3.</td>
		<td>Oxybutynin</td>
		<td>Approved, Investigational</td>
		<td>For the treatment of overactive bladder.</td>
	</tr>	<tr>
		<td>4.</td>
		<td>Imidafenacin</td>
		<td>Approved, Investigational</td>
		<td>Used in the treatment of overactive bladder [FDA Label].</td>
	</tr>	<tr>
		<td>5.</td>
		<td>Fluvoxamine</td>
		<td>Approved, Investigational</td>
		<td>Indicated predominantly for the management of depression and for Obsessive Compulsive Disorder (OCD) [FDA Label]. Has also been used in the management of bulimia nervosa [2].</td>
	</tr>	<tr>
		<td>6.</td>
		<td>Calcium carbimide</td>
		<td>Approved, Withdrawn</td>
		<td>Calcium carbimide has not been approved by the FDA but the intended indication is for the treatment of alcoholism.[6] This medication was marketed in Canada, United Kingdom and Europe under the trade name of Temposil for the sole use of alcoholism treatment.[9]</td>
	</tr>	<tr>
		<td>7.</td>
		<td>VSF-173</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in sleep disorders.</td>
	</tr>	<tr>
		<td>8.</td>
		<td>Facinicline</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in alzheimer's disease, neurologic disorders, and schizophrenia and schizoaffective disorders.</td>
	</tr>	<tr>
		<td>9.</td>
		<td>JB991</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in psoriasis and psoriatic disorders and skin infections/disorders.</td>
	</tr>	<tr>
		<td>10.</td>
		<td>SGS518</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in neurologic disorders and schizophrenia and schizoaffective disorders.</td>
	</tr>	<tr>
		<td>11.</td>
		<td>prGCD</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in metabolic disease and neurologic disorders.</td>
	</tr>	<tr>
		<td>12.</td>
		<td>TD-2749</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in constipation, gastrointestinal diseases and disorders (miscellaneous), gastroparesis, and irritable bowel syndrome (IBS).</td>
	</tr>	<tr>
		<td>13.</td>
		<td>LU-31130</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in psychosis and schizophrenia and schizoaffective disorders.</td>
	</tr>	<tr>
		<td>14.</td>
		<td>Col-118</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in skin infections/disorders.</td>
	</tr>	<tr>
		<td>15.</td>
		<td>RPI-78M</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in multiple sclerosis, neurologic disorders, and pain (acute or chronic).</td>
	</tr>	<tr>
		<td>16.</td>
		<td>Mito-4509</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in alzheimer's disease, neurologic disorders, parkinson's disease, and retinal disorders (unspecified).</td>
	</tr>	<tr>
		<td>17.</td>
		<td>ABT-560</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in neurologic disorders.</td>
	</tr>	<tr>
		<td>18.</td>
		<td>Sotirimod</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in actinic keratosis and skin infections/disorders.</td>
	</tr>	<tr>
		<td>19.</td>
		<td>LX6171</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in alzheimer's disease, attention deficit/hyperactivity disorder (ADHD), dementia, neurologic disorders, and schizophrenia and schizoaffective disorders.</td>
	</tr>	<tr>
		<td>20.</td>
		<td>GW 597599</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in adverse effects (chemotherapy), anxiety disorders, depression, and gastrointestinal diseases and disorders (miscellaneous).</td>
	</tr>	<tr>
		<td>21.</td>
		<td>OPC-51803</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in nocturia (frequent nighttime urination) and urinary incontinence.</td>
	</tr>	<tr>
		<td>22.</td>
		<td>Opebacan</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in crohn's disease, congenital anomaly (unspecified), cardiovascular disorders, pediatric indications, and burns and burn infections.</td>
	</tr>	<tr>
		<td>23.</td>
		<td>Ilodecakin</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in inflammatory disorders (unspecified), crohn's disease, and rheumatoid arthritis.</td>
	</tr>	<tr>
		<td>24.</td>
		<td>KW-7158</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in urinary incontinence.</td>
	</tr>	<tr>
		<td>25.</td>
		<td>NX-1207</td>
		<td>Investigational</td>
		<td>Investigated for use/treatment in benign prostatic hyperplasia.</td>
	</tr></table>
<div class="footer"> Copyright &copy : IIT Kanpur
</div>	
</div>
</body>
</html>